Cargando…

Novel Chimeric Protein Vaccines Against Clostridium difficile Infection

Clostridium difficile infection (CDI) is the leading cause of world-wide nosocomial acquired diarrhea in adults. Active vaccination is generally accepted as a logical and cost-effective approach to prevent CDI. In this paper, we have generated two novel chimeric proteins; one designated Tcd169, comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shaohui, Wang, Yuanguo, Cai, Ying, Kelly, Ciaran P., Sun, Xingmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204379/ https://www.ncbi.nlm.nih.gov/pubmed/30405630 http://dx.doi.org/10.3389/fimmu.2018.02440

Ejemplares similares

Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection
por: Wang, Shaohui, et al.
Publicado: (2022)

Immunoinformatics Approach Toward the Introduction of a Novel Multi-Epitope Vaccine Against Clostridium difficile
por: Tan, Caixia, et al.
Publicado: (2022)

Corrigendum: Immunoinformatics approach toward the introduction of a novel multi-epitope vaccine against Clostridium difficile
por: Tan, Caixia, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC
por: Ghose, Chandrabali, et al.
Publicado: (2016)

The Enterotoxicity of Clostridium difficile Toxins
por: Sun, Xingmin, et al.
Publicado: (2010)

A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters
por: Wang, Yuan-Kai, et al.
Publicado: (2015)

Mucosal Vaccination Strategies against Clostridioides difficile Infection
por: Heuler, Joshua, et al.
Publicado: (2023)

Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence
por: Kelly, Ciaran P, et al.
Publicado: (2017)

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection
por: Schmidt, Diane J., et al.
Publicado: (2016)

Design and characterization of a novel lytic protein against Clostridium difficile
por: Wang, Meng, et al.
Publicado: (2022)

Clostridium difficile outbreaks: prevention and treatment strategies
por: Martinez, Fernando J, et al.
Publicado: (2012)

Genomic and Phenotypic Characterization of the Nontoxigenic Clostridioides difficile Strain CCUG37785 and Demonstration of Its Therapeutic Potential for the Prevention of C. difficile Infection
por: Wang, Shaohui, et al.
Publicado: (2022)

A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Clostridioides difficile Infection in Mice
por: Peng, Zhong, et al.
Publicado: (2019)

Identification of Toxemia in Patients with Clostridium difficile Infection
por: Yu, Hua, et al.
Publicado: (2015)

Targeting Clostridium difficile Surface Components to Develop Immunotherapeutic Strategies Against Clostridium difficile Infection
por: Péchiné, Séverine, et al.
Publicado: (2018)

In silico designing of vaccine candidate against Clostridium difficile
por: Basak, Srijita, et al.
Publicado: (2021)

Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile
por: Bruxelle, Jean-François, et al.
Publicado: (2017)

Membrane Cholesterol Is Crucial for Clostridium difficile Surface Layer Protein Binding and Triggering Inflammasome Activation
por: Chen, Yu, et al.
Publicado: (2020)

Clostridium difficile infections in China()
por: Jin, Ke, et al.
Publicado: (2010)

Clostridium difficile Infection
por: Feuerstadt, Paul
Publicado: (2015)

Clostridium difficile infection
por: Geller, Stephen A., et al.
Publicado: (2014)

Clostridium difficile Infection
por: Magdesian, K. Gary
Publicado: (2003)

Novel Antimicrobials for the Treatment of Clostridium difficile Infection
por: Petrosillo, Nicola, et al.
Publicado: (2018)

Evaluation of the Xpert Clostridium difficile Assay for the Diagnosis of Clostridium difficile Infection
por: Shin, Saeam, et al.
Publicado: (2012)

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile
por: Donald, Robert G. K., et al.
Publicado: (2013)

Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium
por: Yang, Guilin, et al.
Publicado: (2008)

Accuracy of Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection: A meta analysis
por: Bai, Yuanyuan, et al.
Publicado: (2017)

Acid Suppression Therapy Does Not Predispose to Clostridium difficile Infection: The Case of the Potential Bias
por: Novack, Lena, et al.
Publicado: (2014)

Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa
por: Wan, Chuang, et al.
Publicado: (2019)

ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against Ascaris suum Infection
por: Gazzinelli-Guimarães, Ana Clara, et al.
Publicado: (2021)

Clostridium difficile infection: review
por: Czepiel, Jacek, et al.
Publicado: (2019)

Gold Nanoclusters as an Antibacterial Alternative Against Clostridium difficile
por: Yang, Huan, et al.
Publicado: (2020)

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection
por: Vedantam, Gayatri, et al.
Publicado: (2018)

Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection
por: Džunková, Mária, et al.
Publicado: (2016)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

1655 Lack of Adherence to SHEA-IDSA Treatment Guidelines for Severe Clostridium difficile Infection is Associated with Increased Mortality
por: Patel, Ishan, et al.
Publicado: (2014)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Butyrate Protects against Clostridium difficile Infection by Regulating Bile Acid Metabolism
por: Wang, Siqi, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ibfdp9tc5asfvdhvvulr9kd5n8